{"id":"cytisine","rwe":[{"pmid":"41887411","year":"2026","title":"Electronic cigarettes for smoking cessation: An overview of systematic reviews and evidence and gap map.","finding":"","journal":"Addiction (Abingdon, England)","studyType":"Clinical Study"},{"pmid":"41885781","year":"2026","title":"An evaluation of cytisinicline for smoking cessation in adult smokers.","finding":"","journal":"Expert opinion on pharmacotherapy","studyType":"Clinical Study"},{"pmid":"41885134","year":"2026","title":"Receptor selectivity of cytisinicline: minimal 5-HT3 binding may explain lower incidence of nausea in smoking cessation therapy.","finding":"","journal":"Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco","studyType":"Clinical Study"},{"pmid":"41873185","year":"2026","title":"Molecular basis of polyphagy: The detoxification gene HcGST18 underlies host plant adaptation in the Hyphantria cunea.","finding":"","journal":"Insect science","studyType":"Clinical Study"},{"pmid":"41858278","year":"2026","title":"Antitumor Cytisine-Platinum(IV) Prodrugs Potentiate Crosstalk between Endoplasmic Reticulum and Mitochondria through Calcium Overload Accompanied by Immunogenic Cell Death.","finding":"","journal":"Journal of medicinal chemistry","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Neuronal acetylcholine receptor subunit alpha-7","category":"target"},{"label":"CHRNA7","category":"gene"},{"label":"Active","category":"status"},{"label":"Smoking cessation assistance","category":"indication"},{"label":"Pfizer Inc.","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=cytisine","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:54:30.287033+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:54:37.206823+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=cytisine","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:54:38.033722+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Neuronal acetylcholine receptor; alpha4/beta2 partial agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:54:38.578511+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL497939/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:54:38.491823+00:00"}},"allNames":"tabex","offLabel":[],"synonyms":["cytisine","baptitoxine","tabex"],"timeline":[],"aiSummary":"Tabex (cytisine) is a small molecule developed by Pfizer Inc. that targets the neuronal acetylcholine receptor subunit alpha-7 to aid in smoking cessation. It is a non-nicotine prescription medication that works by activating the brain's reward system and reducing cravings for nicotine. Tabex is currently owned by Pfizer Inc. and is approved for use in certain countries, although its commercial status and availability may vary. As a smoking cessation aid, Tabex is used to help individuals overcome nicotine addiction.","approvals":[{"date":"","orphan":false,"company":"","regulator":"Health Canada"}],"brandName":"Tabex","ecosystem":[{"indication":"Smoking cessation assistance","otherDrugs":[{"name":"bupropion","slug":"bupropion","company":"Glaxosmithkline"},{"name":"nicotine","slug":"nicotine","company":"Sanofi Aventis Us"},{"name":"varenicline","slug":"varenicline","company":"Pfizer Inc"}],"globalPrevalence":null}],"mechanism":{"target":"Neuronal acetylcholine receptor subunit alpha-7","targets":[{"gene":"CHRNA7","source":"DrugCentral","target":"Neuronal acetylcholine receptor subunit alpha-7","protein":"Neuronal acetylcholine receptor subunit alpha-7"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Tabex (cytisine) is a partial agonist of the neuronal acetylcholine receptor subunit alpha-7 (nAChRα7), which is involved in the regulation of the brain's reward system and nicotine addiction. By activating this receptor, Tabex reduces the release of dopamine, a neurotransmitter associated with pleasure and reward, thereby decreasing the motivation to smoke."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5217","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=cytisine","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=cytisine","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:26:40.583338","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:54:40.380237+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"acetylcholine","drugSlug":"acetylcholine","fdaApproval":"1973-10-09","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"atracurium","drugSlug":"atracurium","fdaApproval":"1983-11-23","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"bupropion","drugSlug":"bupropion","fdaApproval":"1985-12-30","patentExpiry":"Jun 27, 2026","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"carbachol","drugSlug":"carbachol","fdaApproval":"1972-09-28","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"ivermectin","drugSlug":"ivermectin","fdaApproval":"1996-11-22","patentExpiry":"Mar 13, 2034","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"levomenol","drugSlug":"levomenol","fdaApproval":"","relationship":"same-target"},{"drugName":"mecamylamine","drugSlug":"mecamylamine","fdaApproval":"1956-03-01","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"naltrexone","drugSlug":"naltrexone","fdaApproval":"1984-11-20","patentExpiry":"Oct 15, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"nicotine","drugSlug":"nicotine","fdaApproval":"1991-11-07","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"trimetaphan","drugSlug":"trimetaphan","fdaApproval":"","relationship":"same-target"}],"genericName":"cytisine","indications":{"approved":[{"name":"Smoking cessation assistance","source":"DrugCentral","snomedId":384742004,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"acetylcholine","brandName":"acetylcholine","genericName":"acetylcholine","approvalYear":"1973","relationship":"same-target"},{"drugId":"atracurium","brandName":"atracurium","genericName":"atracurium","approvalYear":"1983","relationship":"same-target"},{"drugId":"bupropion","brandName":"bupropion","genericName":"bupropion","approvalYear":"1985","relationship":"same-target"},{"drugId":"carbachol","brandName":"carbachol","genericName":"carbachol","approvalYear":"1972","relationship":"same-target"},{"drugId":"ivermectin","brandName":"ivermectin","genericName":"ivermectin","approvalYear":"1996","relationship":"same-target"},{"drugId":"levomenol","brandName":"levomenol","genericName":"levomenol","approvalYear":"","relationship":"same-target"},{"drugId":"mecamylamine","brandName":"mecamylamine","genericName":"mecamylamine","approvalYear":"1956","relationship":"same-target"},{"drugId":"naltrexone","brandName":"naltrexone","genericName":"naltrexone","approvalYear":"1984","relationship":"same-target"},{"drugId":"nicotine","brandName":"nicotine","genericName":"nicotine","approvalYear":"1991","relationship":"same-target"},{"drugId":"trimetaphan","brandName":"trimetaphan","genericName":"trimetaphan","approvalYear":"","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT03654105","phase":"PHASE2","title":"Screening and Multiple Intervention on Lung Epidemics","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2019-07-23","conditions":["Inflammation","Smoking Cessation","Diet Modification","Physical Activity","Lung Cancer"],"enrollment":2000,"completionDate":"2026-12-31"},{"nctId":"NCT05766046","phase":"NA","title":"Lung Cancer Prevention Screening Programme in Italy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ugo Pastorino","startDate":"2022-09-17","conditions":["Lung Cancer","COPD (Chronic Obstructive Pulmonary Disease) With Acute Lower Respiratory Infection","Cardiovascular Diseases"],"enrollment":7324,"completionDate":"2026-12-31"},{"nctId":"NCT07274475","phase":"NA","title":"Smoking Harm Reduction Using E-cigarettes and Cytisine","status":"NOT_YET_RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2026-05-01","conditions":["Tobacco Smoking","Harm Reduction","Nicotine"],"enrollment":6000,"completionDate":"2028-03"},{"nctId":"NCT03249428","phase":"NA","title":"Cytisine vs Nicotine Replacement Therapy","status":"ENROLLING_BY_INVITATION","sponsor":"Ottawa Hospital Research Institute","startDate":"2025-11-04","conditions":["Tobacco Dependence","COPD Asthma","Mental Illness","Substance Use"],"enrollment":200,"completionDate":"2027-03"},{"nctId":"NCT06832085","phase":"PHASE4","title":"Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation","status":"RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2025-04-30","conditions":["Tobacco"],"enrollment":150,"completionDate":"2027-10-30"},{"nctId":"NCT05729243","phase":"PHASE4","title":"Cytisine for Smoking Cessation","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2023-02-08","conditions":["Tobacco Use Disorder","Alcohol Use Disorder","Smoking Cessation"],"enrollment":20,"completionDate":"2025-12-12"},{"nctId":"NCT07392125","phase":"PHASE3","title":"Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes","status":"NOT_YET_RECRUITING","sponsor":"Achieve Life Sciences","startDate":"2026-05-15","conditions":["Vaping Cessation"],"enrollment":800,"completionDate":"2027-09-30"},{"nctId":"NCT04576949","phase":"PHASE3","title":"A Study of Cytisinicline for Smoking Cessation in Adult Smokers","status":"COMPLETED","sponsor":"Achieve Life Sciences","startDate":"2020-10-13","conditions":["Smoking Cessation"],"enrollment":810,"completionDate":"2021-12-23"},{"nctId":"NCT05431387","phase":"PHASE2","title":"A Study of Cytisinicline for Vaping Cessation in Adult Smokers","status":"COMPLETED","sponsor":"Achieve Life Sciences","startDate":"2022-07-13","conditions":["Vaping","E-Cig Use"],"enrollment":160,"completionDate":"2023-02-28"},{"nctId":"NCT05206370","phase":"PHASE3","title":"A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers","status":"COMPLETED","sponsor":"Achieve Life Sciences","startDate":"2022-01-20","conditions":["Smoking Cessation"],"enrollment":792,"completionDate":"2023-03-21"},{"nctId":"NCT06617312","phase":"PHASE2","title":"Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2024-12-05","conditions":["Smoking Cessation","Tobacco Use Disorder"],"enrollment":64,"completionDate":"2026-12"},{"nctId":"NCT06435221","phase":"PHASE3","title":"Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers","status":"COMPLETED","sponsor":"Achieve Life Sciences","startDate":"2024-05-28","conditions":["Smoking Cessation","Vaping Cessation"],"enrollment":479,"completionDate":"2025-10-06"},{"nctId":"NCT05631938","phase":"PHASE1","title":"Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Dose","status":"COMPLETED","sponsor":"Achieve Life Sciences","startDate":"2023-01-10","conditions":["Renal Impairment"],"enrollment":44,"completionDate":"2023-09-04"},{"nctId":"NCT06945770","phase":"NA","title":"Web-based Smoking Intervention as an add-on to Routine Smoking Cessation Clinical Treatment","status":"COMPLETED","sponsor":"Ege University","startDate":"2024-05-01","conditions":["Smoking Cessation"],"enrollment":208,"completionDate":"2025-01-01"},{"nctId":"NCT06885970","phase":"","title":"The Effect of Cytisine Treatment for Smoking Cessation on Cardiovascular Function in Adult Smokers","status":"RECRUITING","sponsor":"University of Athens","startDate":"2024-11-12","conditions":["Smoking Cessation","Arterial Stiffness","Endothelial Dysfunction"],"enrollment":200,"completionDate":"2025-08-10"},{"nctId":"NCT05311085","phase":"PHASE3","title":"Cytisine and E-cigarettes With Supportive Text-messaging for Smoking Cessation (Cess@Tion)","status":"COMPLETED","sponsor":"University of Auckland, New Zealand","startDate":"2022-05-05","conditions":["Smoking Cessation"],"enrollment":807,"completionDate":"2024-07-26"},{"nctId":"NCT05736224","phase":"PHASE1","title":"Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen","status":"COMPLETED","sponsor":"Yale University","startDate":"2023-05-15","conditions":["Skin Cancer"],"enrollment":30,"completionDate":"2023-09-01"},{"nctId":"NCT05102123","phase":"PHASE3","title":"PeRiopEratiVE SmokiNg CessaTion Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Population Health Research Institute","startDate":"2024-01-15","conditions":["Smoking (Tobacco) Addiction","Smoking Cessation"],"enrollment":1720,"completionDate":"2027-01-01"},{"nctId":"NCT04126135","phase":"PHASE4","title":"Comparative Effectiveness of Cystine Versus Nicotine Replacement Therapy","status":"COMPLETED","sponsor":"Loma Linda University","startDate":"2022-01-27","conditions":["Nicotine Addiction"],"enrollment":1307,"completionDate":"2024-04-20"},{"nctId":"NCT06579846","phase":"PHASE4","title":"12-Month Efficacy of Exercise and Cytisinicline for Tobacco Abstinence","status":"NOT_YET_RECRUITING","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2025-01-01","conditions":["Smoking Cessation"],"enrollment":150,"completionDate":"2025-12-31"},{"nctId":"NCT06439303","phase":"","title":"Analysis and Evaluation of Smoking Treatment With Cytisine","status":"RECRUITING","sponsor":"Regina Elena Cancer Institute","startDate":"2024-03-20","conditions":["Moderate or Severe Tobacco Use Disorder"],"enrollment":65,"completionDate":"2024-06-20"},{"nctId":"NCT04286295","phase":"NA","title":"Cytisine Compared to Combination NRT in Relapsed Smokers","status":"TERMINATED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2022-03-14","conditions":["Smoking Cessation","Coronary Artery Disease"],"enrollment":13,"completionDate":"2023-11-07"},{"nctId":"NCT05981768","phase":"PHASE1","title":"Study to Evaluate Effect of Food on Bioavailability of Single 3 mg Tablet and Pharmacokinetics (PK) of Multiple 3 mg Doses in Healthy Adult Smokers","status":"COMPLETED","sponsor":"Achieve Life Sciences","startDate":"2023-08-08","conditions":["Smoking Cessation"],"enrollment":30,"completionDate":"2023-09-21"},{"nctId":"NCT05566288","phase":"PHASE1","title":"Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy Smokers","status":"COMPLETED","sponsor":"Achieve Life Sciences","startDate":"2022-10-17","conditions":["Smoking Cessation"],"enrollment":27,"completionDate":"2022-12-23"},{"nctId":"NCT04015414","phase":"PHASE3","title":"Varenicline Versus Cytisine for Smoking Cessation in Primary Care Setting","status":"COMPLETED","sponsor":"University of Zagreb","startDate":"2020-07-14","conditions":["Smoking Cessation"],"enrollment":352,"completionDate":"2022-11-01"},{"nctId":"NCT02957786","phase":"PHASE3","title":"Cytisine Versus Varenicline for Smoking Cessation","status":"COMPLETED","sponsor":"University of Auckland, New Zealand","startDate":"2017-09-18","conditions":["Smoking Cessation"],"enrollment":679,"completionDate":"2019-10-10"},{"nctId":"NCT04784702","phase":"","title":"Smoking Cessation in Patients After Coronary Angiography","status":"COMPLETED","sponsor":"Centre of Postgraduate Medical Education","startDate":"2014-08-05","conditions":["Coronary Artery Disease"],"enrollment":122,"completionDate":"2017-01-30"},{"nctId":"NCT02797587","phase":"PHASE2,PHASE3","title":"Studying Partial-agonists for Ethanol and Tobacco Elimination in Russians With HIV (St PETER HIV)","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-19","conditions":["HIV Infection","Alcohol Use","Smoking"],"enrollment":400,"completionDate":"2020-12-15"},{"nctId":"NCT03848208","phase":"PHASE1","title":"A Single Dose-escalation Study of Cytisine in Adult Smokers","status":"COMPLETED","sponsor":"Achieve Life Sciences","startDate":"2019-02-28","conditions":["Smoking Cessation"],"enrollment":74,"completionDate":"2019-09-12"},{"nctId":"NCT03709823","phase":"PHASE2","title":"Trial of Cytisine in Adult Smokers","status":"COMPLETED","sponsor":"Achieve Life Sciences","startDate":"2018-11-13","conditions":["Smoking Cessation"],"enrollment":254,"completionDate":"2019-04-23"},{"nctId":"NCT03303911","phase":"PHASE1,PHASE2","title":"A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers","status":"TERMINATED","sponsor":"Achieve Life Sciences","startDate":"2017-10-06","conditions":["Smoking Cessation"],"enrollment":26,"completionDate":"2018-10-05"},{"nctId":"NCT03509948","phase":"PHASE1","title":"A Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New Formulation","status":"COMPLETED","sponsor":"Achieve Life Sciences","startDate":"2018-04-27","conditions":["Smoking Cessation"],"enrollment":13,"completionDate":"2018-06-12"},{"nctId":"NCT02585024","phase":"PHASE1","title":"Cytisine Pharmacokinetics and Dose Response (C-DRAKS 3 and C-DRAKS 4)","status":"TERMINATED","sponsor":"University of Auckland, New Zealand","startDate":"2016-02","conditions":["Smoking Cessation"],"enrollment":35,"completionDate":"2019-03"},{"nctId":"NCT03268343","phase":"PHASE1","title":"A Study in Healthy Volunteers to Investigate the Effect of Food on the Bioavailability of Cytisine","status":"COMPLETED","sponsor":"Achieve Life Sciences","startDate":"2017-08-08","conditions":["Smoking Cessation"],"enrollment":24,"completionDate":"2017-09-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"1ZI8CA9FWW","CHEBI":"CHEBI:4055","INN_ID":"11015","RXNORM":"1723152","UMLSCUI":"C0056913","chemblId":"CHEMBL497939","ChEMBL_ID":"CHEMBL497939","KEGG_DRUG":"D07770","DRUGBANK_ID":"DB09028","PDB_CHEM_ID":" C5E","PUBCHEM_CID":"10235","SNOMEDCT_US":"76283008","IUPHAR_LIGAND_ID":"5347","MESH_SUPPLEMENTAL_RECORD_UI":"C004712"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Pfizer","relationship":"Current Owner"}],"publicationCount":1013,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 26","pmid":"41887411","title":"Electronic cigarettes for smoking cessation: An overview of systematic reviews and evidence and gap map.","journal":"Addiction (Abingdon, England)"},{"date":"2026 Mar 26","pmid":"41885781","title":"An evaluation of cytisinicline for smoking cessation in adult smokers.","journal":"Expert opinion on pharmacotherapy"},{"date":"2026 Mar 26","pmid":"41885134","title":"Receptor selectivity of cytisinicline: minimal 5-HT3 binding may explain lower incidence of nausea in smoking cessation therapy.","journal":"Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco"},{"date":"2026 Mar 23","pmid":"41873185","title":"Molecular basis of polyphagy: The detoxification gene HcGST18 underlies host plant adaptation in the Hyphantria cunea.","journal":"Insect science"},{"date":"2026 Mar 20","pmid":"41858278","title":"Antitumor Cytisine-Platinum(IV) Prodrugs Potentiate Crosstalk between Endoplasmic Reticulum and Mitochondria through Calcium Overload Accompanied by Immunogenic Cell Death.","journal":"Journal of medicinal chemistry"}],"_healthCanadaChecked":true,"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small Molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":5,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:54:40.380237+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}